RCT | Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial – The Lancet (link to abstract – $ for full-text)

News Release: Progress in search for alopecia areata treatment for adolescents  – Yale News

Commentary on Twitter

Ritlecitinib might be a treatment option for alopecia areata in patients aged 12 years and older, suggests a new study: https://t.co/jKUxEbo4AZ

Below, a graphical abstract ? pic.twitter.com/JIJtTGHeE4

— The Lancet (@TheLancet) April 17, 2023